National Monitoring and Evaluation of the Indigenous Chronic Disease Package First Monitoring

KPMG

National Monitoring and Evaluation of the Indigenous Chronic Disease PackageFirst Monitoring Report2010-11Appendices

Paper-based publications

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to .

Internet sites

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via
e-mail to .

This report has been independently prepared for the Australian Government Department of Health by KPMG Australia, and does not necessarily represent the views of the Australian Government.

National Monitoring and Evaluation of the Indigenous

Chronic Disease Package

First Monitoring Report

2010-11

Appendices

Table of Contents

Disclaimer

Appendix A.Overview of the ICDP

Appendix B.Overview of the evaluation

Appendix C.Methodology

Appendix D.Regional Forum summary

Appendix E.Whole of ICDP evaluation table

Appendix F.Subsidising PBS Medicine Co-payment measure data appendix

Appendix G.Higher utilisation of MBS and PBS data appendix

Appendix H.PIP Indigenous Health Incentive data appendix

Appendix I.Evaluation Framework tables

KPMG is an Australian partnership and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved. Printed in Australia. KPMG and the KPMG logo are registered trademarks of KPMG International. Liability limited by a scheme approved under Professional Standards Legislation.

National Monitoring and Evaluation of the Indigenous

Chronic Disease Package

First Monitoring Report

2010-11

Appendices

List of Figures and Tables

Figure 1: Number of patients dispensed at least one CtG script, by quarter, by age group, Australia.

Figure 2: Number of CtG Scripts dispensed, by quarter, by age group, Australia.

Figure 3: Number of CtG scripts dispensed per patient in first and fourth quarter of the measure.

Figure 4: CtG Scripts dispensed in May quarter 2011, by Broad ATC, by age group, Australia.

Figure 5: Share of total CtG scripts dispensed within each broad ATC, by age group, Australia, May quarter 2011.

Figure 6: Share of CtG scripts dispensed within each age group, by broad ATC, Australia, May quarter 2011.

Figure 7: Patients dispensed at least one CtG script in each quarter, by remoteness, Australia.

Figure 8: Number of CtG scripts dispensed for each quarter, by remoteness, Australia.

Figure 9: CtG scripts per patient for first and fourth quarter of measure, by remoteness, Australia.

Figure 10: Share of CtG scripts dispensed in May quarter 2011 within remoteness areas, by broad ATC, Australia.

Figure 11: CtG scripts dispensed per patient for first and fourth quarters of measure, by patient category, Australia.

Figure 12: Share of CtG scripts dispensed within patient category, by broad ATC, May quarter 2011 Australia.

Figure 13: Patients dispensed at least one CtG script, by quarter, by jurisdiction.

Figure 14: CtG scripts dispensed per patient for first and fourth quarter of measure, by jurisdiction.

Figure 15: Share of CtG scripts dispensed within jurisdictions, by broad ATC,May quarter 2011, Australia.

Figure 16: Australia.

Figure 17: Share of CtG scripts dispensed in first and fourth quarters of measure, by broad ACT, Australia.

Figure 18: Numbers of CtG scripts dispensed and S100 RAAHS items supplied, by jurisdiction, May quarter 2011.

Figure 19: Share of items within S100 RAAHS and CtG, by broad ATC, Australia, May quarter 2011.

Figure 20: Total utilisation by quarter - Australia: Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 21: Per 100 capita utilisation by quarter - Australia: Selected MBS items (services); and CtG scripts. Source: KPMG

Figure 22: Total utilisation by quarter - NSW Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 23: Per 100 capita utilisation by quarter – NSW: Selected MBS items; and CtG scripts. Source: KPMG

Figure 24: Total utilisation by quarter – Qld: Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 25: Per 100 capita utilisation by quarter – Qld: Selected MBS items; and CtG scripts. Source: KPMG

Figure 26: Total utilisation by quarter – WA: Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 27: Per 100 capita utilisation by quarter – WA. Selected MBS items; and CtG scripts. Source: KPMG

Figure 28: Total utilisation by quarter – NT: Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 29: Per 100 capita utilisation by quarter – NT: Selected MBS items; and CtG scripts. Source: KPMG

Figure 30: Total utilisation by quarter – Vic: Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 31: Per 100 capita utilisation by quarter – Vic: Selected MBS items; and CtG scripts. Source: KPMG

Figure 32: Total utilisation by quarter – SA: Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 33: Per 100 capita utilisation by quarter – SA. Selected MBS items; and CtG scripts. Source: KPMG

Figure 34: Total utilisation by quarter – Tas: Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 35: Per 100 capita utilisation by quarter – Tas. Selected MBS items; and CtG scripts. Source: KPMG

Figure 36: Total utilisation by quarter – NT: Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 37: Per 100 capita utilisation by quarter – ACT. Selected MBS items; and CtG scripts. Source: KPMG

Figure 38: Total utilisation by quarter – Major Cities: Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 39: Per 100 capita utilisation by quarter – Major Cities. Selected MBS items; and CtG scripts. Source: KPMG

Figure 40: Total utilisation by quarter – Inner and Outer Regional: Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 41: Per 100 capita utilisation by quarter – Inner and Outer Regional. Selected MBS items; and CtG scripts. Source: KPMG

Figure 42: Total utilisation by quarter – Remote and Very Remote: Selected MBS items use (715, 10987, 81300 to 81360) as total services; and Selected PBS items use (CtG scripts) as a total. Source: KPMG

Figure 43: Per 100 capita utilisation by quarter – Remote and Very Remote. Selected MBS items; and CtG scripts. Source: KPMG

Figure 44: Aboriginal Health Assessments by gender. Source: KPMG

Figure 45: Aboriginal Health Assessments by age group. Source: KPMG

Figure 46: Unique providers of health assessments at the national level by quarter. Source: KPMG

Figure 47: Average health assessments per unique provider for Australia. Source: KPMG

Table 1: Whole of ICDP evaluation medium-term results table. Source: KPMG

Table 2: Whole of ICDP evaluation early results table. Source: KPMG

Table 3: Whole of ICDP evaluation outputs table. Source: KPMG

Table 4: CtG scripts and other PBS scripts dispensed by ATC for May quarter 2011.

Table 5: Selected MBS and PBS utilisation, total and per 100 capita by quarter - Australia.

Table 6: Selected MBS and PBS utilisation, total and per 100 capita by quarter - NSW.

Table 7: Selected MBS and PBS utilisation, total and per 100 capita by quarter - Qld.

Table 8: Selected MBS and PBS utilisation, total and per 100 capita by quarter - WA.

Table 9: Selected MBS and PBS utilisation, total and per 100 capita by quarter - NT.

Table 10: Selected MBS and PBS utilisation, total and per 100 capita by quarter - Vic.

Table 11: Selected MBS and PBS utilisation, total and per 100 capita by quarter - SA.

Table 12: Selected MBS and PBS utilisation, total and per 100 capita by quarter -Tas.

Table 13: Selected MBS and PBS utilisation, total and per 100 capita by quarter – ACT.

Table 14: Selected MBS and PBS utilisation, total and per 100 capita by quarter - Major Cities.

Table 15: Selected MBS and PBS utilisation, total and per 100 capita by quarter - Inner and Outer Regional.

Table 16: Selected MBS and PBS utilisation, total and per 100 capita by quarter – Remote and Very Remote.

Table 17: Practice registrations by jurisdiction and Medicare quarter.

Table 18: Practice registrations by remoteness and Medicare quarter.

Table 19: Practice registrations by Medicare quarter and practice type.

Table 20: Patient registrations in 2010 by jurisdiction.

Table 21: Patient registrations in 2010 by remoteness.

Table 22: Patients registered in 2010 by practice type.

Table 23: Patients re-registered and registered in 2011 and 2010 by jurisdiction

Table 24: Patients re-registered and registered in 2011 and 2010 by remoteness

Table 25: Patients re-registered and registered in 2011 and 2010 by practice type

Table 26: Patients registered and the type of payment those patients triggered in 2010 by jurisdiction

Table 27: Patients registered and the type of payment those patients triggered in 2010 by remoteness

Table 28: Patients registered and the type of payment those patients triggered in 2010 by practice type

Table 29: Patients and practices registered by type of practices.

Table 30: PIP Indigenous Health Incentive payment statistics May 2010 and May 2011.

Table 31: Practice reach of PIP Indigenous Health Incentive by jurisdiction at May 2011.

Table 32: Persons with one or more chronic conditions.

Table 33: Estimates of PIP Indigenous Health Incentive reach for the Aboriginal and Torres Strait Islander population aged 15 years and over by jurisdiction, 2010

Table 34: Estimates of PIP Indigenous Health Incentive reach for the Aboriginal and Torres Strait Islander population aged 15 years and over by remoteness, 2010

Table 35: Evaluation Framework Table for National Action to Reduce Indigenous Smoking Rates (A1)

Table 36: Evaluation Framework Table for Helping Indigenous Australians Reduce Their Risk of Chronic Disease (A2)

Table 37: Evaluation Framework Table for Local Indigenous Community Campaigns to Promote Better Health (A3)

Table 38: Evaluation Framework Table for Supporting Primary Care Providers to Coordinate Chronic Disease Management (B3b)

Table 39: Evaluation Framework Table for Improving Indigenous Participation in Health Care through Chronic Disease Self Management (B4)

Table 40: Evaluation Framework Table for Increasing Access to Specialist and Multidisciplinary Team Care (B5a)

Table 41: Evaluation Framework Table for Increasing Access to Specialist and Multidisciplinary Team Care (B5b)

Table 42: Evaluation Framework Table for Workforce Support, Education and Training (C1)

Table 43: Evaluation Framework Table for Engaging Divisions of General Practice to Improve Indigenous Access to Mainstream Primary Care (C3)

Table 44: Evaluation Framework Table for Attracting More People to Work in Indigenous Health (C4)

Table 45: Framework Evaluation Table for Clinical Practice and Decision Support Resources (C5)

Disclaimer

Inherent Limitations

This report has been prepared as outlined in the scope section. The services provided in connection with this engagement comprise an advisory engagement which is not subject to Australian Auditing Standards or Australian Standards on Review or Assurance Engagements, and consequently no opinions or conclusions intended to convey assurance have been expressed.

This report has not been prepared on KPMG letterhead and does not contain the KPMG logo, but is presented in an editable format to support web accessibility for the vision impaired. We confirm that the definitive version of this report is that which bears the KPMG logo.

The findings in this report are based on consultation with stakeholders.

No warranty of completeness, accuracy or reliability is given in relation to the statements and representations made by, and the information and documentation provided by the Department of Health personnel and stakeholders consulted as part of the process.

Where appropriate KPMG have indicated within this report the sources of the information provided. We have not sought to independently verify those sources unless otherwise noted within the report.

KPMG is under no obligation in any circumstance to update this report, in either oral or written form, for events occurring after the report has been issued in final form.

The findings in this report have been formed on the above basis.

Third Party Reliance

This report is solely for the purpose set out in the scope section and for the information of the Department of Health, and is not to be used for any other purpose or distributed to any other party without KPMG’s prior written consent.

This report has been prepared at the request of the Department of Health in accordance with the terms of KPMG’s contract. Other than our responsibility to the Department of Health neither KPMG nor any member or employee of KPMG undertakes responsibility arising in any way from reliance placed by a third party on this report. Any reliance placed is that party’s sole responsibility.

National Monitoring and Evaluation of the Indigenous

Chronic Disease Package

First Monitoring Report

2010-11

Appendices

Appendix A.Overview of the ICDP

This Appendix presents an overview of the ICDP.

The ICDP is the Australian Government’s contribution to the National Partnership Agreement on Closing the Gap in Indigenous Health Outcomes (the NPA). The Package comprises a set of 14 interrelated measures that include a range of health promotion and social marketing activities, reforms to existing programs, and new initiatives and funding to increase the size and capacity of health care services to deliver effective care to Aboriginal and Torres Strait Islander people. The ICDP includes funding to monitor and evaluate the Package under the B6 measure.

The National Closing the Gap Initiative involves two targets for Closing the Gap in health outcomes. These targets are:

to close the gap in life expectancy within a generation; and
to halve the gap in mortality rates for Indigenous children under five years of age within a decade.

On 29 November 2008, the Council of Australian Governments (COAG) agreed to a $1.6 billion National Partnership Agreement (NPA) to specifically address the first of the COAG Closing the Gap targets – to close the gap in life expectancy within a generation.

In order to achieve these targets, five priority areas have been established in the NPA:

1.tackling smoking;

2.providing a healthy transition to adulthood;

3.making Indigenous health everyone’s business;

4.delivering effective primary health care services; and

5.better coordinating the patient journey through the health system.

The National Closing the Gap Initiative aims to support change for all Aboriginal and Torres Strait Islander people across Australia, regardless of health and wellbeing status or geographical location. The ICDP is the Australian Government’s contribution to the NPA.

A.1Aims, objectives and principles underpinning the ICDP

The three key priority areas identified for the ICDP are:

Tackling chronic disease risk factors – such as smoking, poor nutrition and lack of exercise. This outcome will be achieved through community education initiatives, new chronic disease prevention and health promotion workers, and implementation of healthy lifestyle and smoking cessation programs provided by Aboriginal and Torres Strait Islander people.
Improving chronic disease management and follow up care – through a comprehensive approach that seeks to encourage greater uptake of health checks and the provision of followup care in a coordinated, accessible and systematic manner. It is intended that this will be achieved through provision of incentives, training and support to health professionals to deliver best practice chronic disease care, improving access to medicines, specialists and primary health care services, and supporting Aboriginal and Torres Strait Islander people to self manage their chronic conditions.
Workforce expansion and support – for the Aboriginal and Torres Strait Islander health workforce. It is intended this will be achieved through marketing activity to attract more people to work in the Indigenous health services sector(IHSs), recruitment of Aboriginal and Torres Strait Islander health workers and provision of training and support to the health workforce, such as access to culturally appropriate clinical guidelines.

The Package comprises a set of 14interrelated measures that include a range of health promotion and social marketing activities, reforms to existing programs, and new initiatives and funding to increase the size and capacity of health care services to deliver effective care to Aboriginal and Torres Strait Islander people.